Society of Investment Professionals in Germany

HealthcareServices&HealthcareSuppliers-EssentialsforaffordableHealthcare-

5thDVFASymposiumLifeSciencefollowedbyaGetTogether

8May2012,from9a.m.

DVFA Center, Frankfurt/Main

5thDVFALifeScienceConference

Supported by

Media Partner

Life Science Conference

Dear attendee, DVFA Committee Life Science is proud to present the 5th DVFA Life Science Conference in Frankfurt/Main. The Life Science Symposium focuses on the issue of how to fund the growing demand for healthcare services and products in the wake of aging populations and the sovereign debt crisis. The growing funding shortfall is acting as a catalyst for necessary structural changes in healthcare and for Healthcare Services Providers & Suppliers. Innovative strategies and affordable products are needed in all areas of healthcare in order to increase efficiency, effectiveness and quality. The care of chronically sick and multimorbid patients represents a formidable challenge to the present system. I am very pleased to welcome you in Frankfurt and wish you an interesting and informative conference. If there is anything DVFA can do to make you feel more comfortable, or if you have questions, please do not hesitate to contact myself or my team any time. Kind regards, Ralf Frank MBA Managing Director DVFA GmbH

3

Life Science Conference

DISCLAIMER

This brochure contains information from sources believed to be reliable but has not been verified or testified. The corporate data provided has been transmitted and converted electronically. Therefore, the information cannot be guaranteed to be secure or error-free as the transmitted and converted information could be intercepted, corrupted, lost or incomplete.

Thus, DVFA does not accept liability for any errors or omissions regarding the contents of this information. The conference brochure is provided for information purposes and should not be construed as a solicitation or offer to buy or sell any securities or related financial instruments.

Any copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

Please note that the data given in this brochure may be rounded. Deviations may thus occur, e.g. regarding percentage figures.

2012 DVFA GmbH

ALL RIGHTS RESERVED. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher and the copyright holder.

Editorial Close: 03 May 2012

4

Life Science Conference

Society of Investment Professionals in Germany

Table of Contents

Page

Programme Symposium ............................................................................................................. 7

Speakers and Moderators .......................................................................................................... 8

Sponsors .................................................................................................................................... 17

Organizational Notes ................................................................................................................ 20

5

Life Science Conference

Programme Symposium

Tuesday, 8 May 2012

08:45 Check-in

09:00 Welcome Ralf Frank, Managing Director, DVFA Dr. Markus Manns, Union Investment Privatfonds and Chairman DVFA Commission Life Science

09:10 Healthcare Services - Essentials for affordable Healthcare - An Introduction Michael Burkhart, Partner, PricewaterhouseCoopers

09:45 Redefining German Health Care - Moving to Value-Based System Dr. Clemens Guth, Managing Director, Artemed Kliniken

10:20 Company Presentation I: Rhön-Klinikum Dr. Erik Hamann, CFO

10:50 Coffee Break 11:10 Company Presentation II: Asklepios Kliniken Stephan Leonhard, CFO

11:45 Panel I: Healthcare Services - Successful Strategies from a Capital Market Perspective Sebastien Buch, Union Investment Privatfonds Michael Burkhart, Partner, PricewaterhouseCoopers Stefan Höfer, Deutsche Börse Dr. Volker Wendel, CFO, AMEOS Gruppe

Moderation: Dr. Christa Bähr, DZ BANK and Chairwoman DVFA Commission Life Science

12:45 Lunch

13:30 Healthcare Suppliers - Essentials for affordable Healthcare - Manuela Müller-Gerndt, Healthcare Leader IBM

14:05 Company Presentation III: NEXUS AG Dr. Ingo Behrendt, CEO

14:40 Company Presentation IV: CompuGroup Medical AG Christian B. Teig, CFO

15:10 Coffee Break

15:30 Company Presentation V: QIAGEN Dr. Stephen Little, VP Global Personalized Healthcare

16:05 Panel II: Healthcare Suppliers - Increase in Quality & Efficiency? Kai Brüning, ApoAsset Management Dr. Stephen Little, VP Global Personalized Healthcare Manuela Müller-Gerndt, Healthcare Leader, IBM Prof. Dr. Jörg Vienken, VP BioSciences, Fresenius Medical Care Deutschland

Moderation: Dr. iur. Dr. med. Adem Koyuncu, Partner, Mayer Brown LLP Rechtsanwälte

17:00 Get Together Subject to modifications!

7

Life Science Conference

Speakers & Moderators Dr. Christa Bähr, CEFA, CFA, DZ BANK AG and Chairwoman DVFA Commission Life Science

Dr. Ingo Behrendt, CEO, NEXUS AG

Kai Brüning, CEFA, Senior Portfolio Manager, ApoAsset Management

Sebastién Buch, CFA, Portfoliomanager, Union Investment Privatfonds

Michael Burkhart, Partner und Leiter Bereich Gesundheitswesen und Pharma, PricewaterhouseCoopers

Dr. Clemens Guth, Managing Director, Artemed Kliniken

Dr. Erik Hamann, CFO, Rhön-Klinikum

Stefan Höfer, Vice President Issuer & Investor Markets, Deutsche Börse AG

Dr. iur. Dr. med. Adem Koyuncu, Partner, Mayer Brown LLP Rechtsanwälte

Stephan Leonhard, CFO, Asklepios Kliniken

Dr. Stephen Little, VP Global Personalized Healthcare, QIAGEN

Dr. Markus Manns, Union Investment Privatfonds and Chairman DVFA Commission Life Science

Manuela Müller-Gerndt, Healthcare Leader, IBM

Christian B. Teig, CFO, CompuGroup Medical AG

Prof. Dr. Jörg Vienken, VP BioSciences, Fresenius Medical Care Deutschland

Dr. Volker Wendel, CFO, AMEOS Gruppe

The following information is provided by the respective speakers and moderators. DVFA cannot assume any responsibility for the correctness and completeness of this information.

8

Life Science Conference Dr. Christa Bähr, CEFA, CFA, DZ BANK AG & Chairwoman DVFA Committee Life Science

Christa Bähr joined DZ BANK Equity Research in January 2000 to build up the Life Science Team. In July 2003 she became group leader of the newly founded group which includes Life Science, Chemicals, Telecoms, Real Estate and Financials. Besides she is in her position as lead analyst healthcare responsible for the fundamental analysis of healthcare stocks. She is CEFA Investment Analyst/DVFA und Chartered Financial Analyst (CFA) and chairwoman of the DVFA Commission Life Science. Following an apprenticeship as bank clerk at Commerzbank AG, she studied

business administration and economics at the University of Cologne. After that she worked as an assistant at the Seminar for Public Finance at the University of Cologne and obtained her doctorate in economics (Dr. rer. pol.) in 1994. Before and during her studies, she worked for Commerzbank AG in Bonn, Cologne and London. From 1994 to 1998, she worked for Bankgesellschaft Berlin AG in Berlin, and from 1998 to 1999 for BHF-BANK AG/ING Group in Frankfurt as investment analyst for pharmaceutical, healthcare, biotechnology and chemical stocks. Dr. Ingo Behrendt, NEXUS AG

Born 1965 in Hamburg, lives in Konstanz, 2 children

Dr. Ingo Behrendt is a member of the board of NEXUS AG since 2000, and is in the position of CEO since 2002.

NEXUS has been growing to one of the leading Healthcare IT companies in the last 10 years. NEXUS AG is listed at Frankfurt Stock exchange.

Mr. Behrendt is trained as a banker, studied business administration at the University of Applied Sciences Worms (Master of Business Administration) and computer science at the University of Konstanz (Diploma in Information Science). In addition, Dr. Behrendt graduated (with a Fulbright scholarship) at Clark University, Massachusetts (USA) from an MBA degree program. At the Technical University of Berlin, Dr. Behrendt gained a Ph.D. in the field of software architecture.

Dr. Behrendt has extensive international experience in the IT business, which he has acquired in various commercial and technical functions in the time of 1992-2000 at Siemens AG. In particular, responsibility for major software development projects and international customer projects were the focus of activities at Siemens AG. As the author of several books and a member of the supervisory board of a nursing home chain, Dr. Behrendt uses his experience also outside of NEXUS AG.

9

Life Science Conference Sébastien Buch, CFA, Union Investment Privatfonds

Sébastien Buch joined the equity portfolio management of Union Investment in January 2005. He is responsible for two equity funds and covers the international health care sector.

From March 2002 to December 2004 Sébastien worked as a senior portfolio manager at DWS Investment in Frankfurt, where he managed three international health care funds. He started his career as a junior portfolio manager in September 2000 at Zurich Investmentgesellschaft mbH in Frankfurt.

Following a vocational training programme at Deutsche Bank in Lörrach, Sébastien studied business administration and economics at the University of Applied Sciences in Aachen and at the Universities of Alicante (Spain) and Lille (France). In the year 2000 he graduated with a degree in business administration and the “maitrise en sciences économiques mention économie internationale”. Kai Brüning, CEFA, apo Asset Management GmbH

Kai Brüning is a Senior Portfolio Manager at apo Asset Management, which is a majority owned subsidiary of Deutsche Apotheker & Ärztebank. He manages global healthcare funds for institutional and private clients. Mr. Brüning works in the healthcare investment area for over a decade. Before joining apo Asset he worked with ADIG/ Cominvest and Deka Investment. Mr. Brüning holds a Diplom-Kaufmann degree from the University of Cologne and is a DVFA/CEFA degree holder. He was awarded by Thomson Extel surveys in the past and is a board member of the DVFA Life Science Commission.

10

Life Science Conference Michael Burkhart, PricewaterhouseCoopers Michael Burkhart ist Partner im Kompetenz-Zentrum Healthcare im Bereich Wirtschaftsprüfung und prüfungsnahe Beratung und Leiter des Bereichs Gesundheitswesen und Pharma bei PricewaterhouseCoopers.

Herr Burkhart verfügt über 14 Jahre Berufserfahrung im Gesundheitswesen, davon insbesondere im Bereich:

Jahresabschlussprüfung von Universitätsklinika - Prüfungsleitung bei Universitätsklinika (Universitätsklinikum

Heidelberg, Universitätsklinikum Marburg, Universitätsklinikum Gießen, Universitätsklinikum Aachen)

- Unterstützung der DFG in Bezug auf die Erstellung von Kriterien zur Transparenzrechnung/Trennungsrechnung

Jahresabschlussprüfung (Einzel- und Konzernabschluss) von Krankenhäusern, Alten- und Pflegeheimen und Reha-Einrichtungen verschiedener Rechtsformen und Größen (inkl. psychiatrischer und neurologischer Einrichtungen), inklusive einer im Prime Segment gelisteten Klinikkette

Prüfung von Businessplänen und Due Diligence bei Alten- und Pflegeheimen und Krankenhäusern

Erstellung von Bilanzierungsrichtlinien für psychiatrische Einrichtungen

Verantwortlicher Partner für Benchmarking Healthcare und psychiatrische Einrichtungen

Mitglied im europäischen EMEA Healthcare Leadership Team

Herr Michael Burkhart absolvierte das Studium der Betriebswirtschaftslehre an der Universität Passau. Er spricht fließend Englisch.

Michael Burkhart ist Wirtschaftsprüfer und Steuerberater. Er gehört PricewaterhouseCoopers seit 1994 an. Dr. Clemens Guth, Artemed Kliniken

Clemens Guth is the chief executive of three German hospitals and a member of the executive board at Artemed Kliniken, a German national hospital provider. Earning his M.D. at Imperial College London, Dr. Guth began his career as a Junior Doctor at the Chelsea & Westminster Hospital in London. Subsequently, he became a health care consultant for McKinsey & Company. After earning his M.B.A. at Harvard Business School with honors, he returned to hospitals but as a manager. Dr. Guth collaborates with Prof. Michael E. Porter on health systems research since

2006 and is a Senior Institute Associate at the Institute for Strategy and Competitiveness at Harvard Business School. He is a scholarship winner of the German National Academic Foundation and the German Academic Exchange Service program.

11

Life Science Conference Dr. Erik Hamann, Rhön-Klinikum

Since 2009 CFO of RHÖN-KLINIKUM AG 2006-2008 Head of RHÖN-KLINIKUM´s Management Controlling 2004-2005 CEO of Mannheim Nursing Home Group 2001-2005 Head of Corporate Development Mannheim University

Hospital 2000-2001 Senior Consultant at Roland Berger’s Healthcare Practice

Stefan Höfer, Deutsche Börse AG

Professional Experience with Deutsche Börse AG A Business Administration graduate, Stefan has over 20 years experience with Deutsche Börse. Starting his career with the ‘Electronic Trading System’ department he moved to the ‘New Market’ team in 1997. From 1999 he managed a number of projects developing exchanges in Central and Eastern Europe. In 2001 Stefan was appointed Head of Marketing for NEWEX Börse AG, the central and eastern European exchange. Since May 2002 he has been Key Account Manager for Life Science Issuers and Listing Partners. Currently his role as Director and Expert includes responsibilities for development and promotion of Deutsche Börse listing

activities in Russia & CIS.

12

Life Science Conference Dr. iur. Dr. med. Adem Koyuncu, Mayer Brown LLP

Dr. Dr. Adem Koyuncu is double qualified as lawyer and medical doctor and is one of the co-chairs of Mayer Brown’s global Life Sciences-practice. He focuses his practice on advising and representing Life Sciences industry clients. His clients include midsize and global and some of the leading pharmaceutical, medical devices and nutrition companies. He also advises investors in the Life Sciences-industry. Prior to joining Mayer Brown, Adem worked for several years in the pharma

industry and practiced as medical doctor. He has an in-depth knowledge of the Life Sciences industry. Adem assists clients in transactions and corporate matters. He also provides advice on compliance, regulatory and liability matters. In 2008 and 2005, he received renowned awards for his legal work. He is named as "often recommended lawyer" for pharma and medical devices law by Germany’s leading legal handbook. Adem is the author of numerous publications and a frequent speaker on Life Sciences industry related topics. He is a lecturer at the Bucerius Law School and the University of Düsseldorf. Adem is fluent in German, Turkish and English. Stephan Leonhard, Asklepios Kliniken

responsible for Accounting, Controlling, Tax, Risk-Management, Corporate Finance, Internal Audit, Insurance, Legal and M&A

with Asklepios since 2002 previously CFO of various companies Dipl.-Kfm. (University of Mannheim) Tax Advisor (Ernst & Young)

Corporate Profile:

With a market share of over 20 percent, the Asklepios Group is one of the three largest operators of private hospitals in Germany. The group’s strategy – which focuses on high-quality, innovation and sustainable growth – has been rewarded with dynamic growth since its formation 26 years ago. With its more than 44000 employees Asklepios runs more than 140 health facilities. At the end of 2011 about 1,7 billion of patients were medicated at facilities of the Asklepios Group.

Asklepios has a strong growth record, is profitable and generates stable cash flows on the basis of a long-term orientated business model. The group also has a sound financial structure and a strong capital base. Asklepios is thus excellently positioned, both strategically and commercially, to actively shape the structural transformation of the German healthcare system.

13

Life Science Conference Dr. Stephen Little, QIAGEN

Dr Stephen Little is a leading figure in the global personalized healthcare and companion diagnostics industry. Co-founder and former CEO of DxS Ltd, Dr Little led the company from its inception in 2001 to become the market leader in the provision of molecular diagnostics for cancer. In September 2009 DxS was acquired by QIAGEN, a global sample and assay company, DxS is now QIAGEN Manchester Ltd, a global Center of Excellence in Companion Diagnostics. Dr Little has over 20 years experience in the pharmaceutical and diagnostics sectors, and as VP of Personalized Healthcare at QIAGEN continues to help shape the personalised medicine marketplace, championing the cause for pharmaceutical partnering and companion

diagnostic provision in healthcare. Manuela Mueller-Gerndt, Healthcare Leader, IBM

Manuela Mueller-Gerndt is a leading management executive in the healthcare industry with a passion for technology and medicine and a proven track record of business results in this market. She started her career 15 years ago in the healthcare industry at one of the Global Players for healthcare. In her current role with IBM, she is focusing on generating proven healthcare outcomes by designing innovative healthcare solutions for the entire healthcare industry in Germany. Her clients include university hospitals, large private owned

hospital chains, public and private healthcare insurance organizations, medical technology companies, pharma/life science organizations as well the Ministry of Health. Typical solutions in the portfolio are healthcare analytics, healthcare transformation projects, health 2.0, telemedicine, e-health and cross-solutions for care coordination, new go-to-market approaches including shared research programs for prevention, chronic diseases, or personalized medicine, genomics and translational medicine. Manuela has owns at IBM people and project responsibility. Prior to her current role she led significant global healthcare projects for SME’s in the medical-device sector i.e. innovative mobile imaging, 3D-visualization, and introduction of flat panel technology in the mobile imaging market. Manuela served for two years as Vice President for Ziehm Imaging GmbH, an innovative medical imaging company where she led the turnaround team and was in charge for strategic product innovations,marketing and education. She started her career at Siemens Medical Solutions, first in charge of strategic healthcare projects, such as solution-driven technological roll-out implementations and new business development for the healthcare industry, then managing the entire global knowledge management and competitive intelligence initiative for Siemens Medical Solutions both for employees and customers around the world. Manuela holds a degree in business administration from the Universities in Munich and Rome. She followed her executive and healthcare technology education at Duke University, M.I.T., Cambridge and Boston University (USA), published books and publications in German, English and Chinese language and is invited speaker and significant influencer at several international healthcare conferences. Manuela is mother of eight year old twins and member of following organizations, where she bridges the world of theory (ideas) and the practical reality for execution: M.I.T. Alumni, Cambridge, U.S.A., Alumni of the Hanns Seidel Foundation Munich, Young Leaders Forum at BMW Foundation Herbert Quandt, Coach for Entrepreneurship at the Chamber of Commerce Munich, Lecturer for SME Leadership and Management at FOM Munich, Member of the German Advisory Council for Global Change (Healthcare) etc.

14

Life Science Conference Dr. Markus Manns, Union Investment Privatfonds GmbH

Markus Manns joined Union Investment in 2000 as Portfolio Manager Life Sciences. He manages the award winning funds Unisector Biopharma and Unisector Gentech and is also Co-chairman of the DVFA Commission Life Science and member of the advisory board of Go-bio, a start-up program from the Federal Ministry of Education and Research (BMBF). Markus Manns graduated from Johannes Gutenberg University Medical School Mainz in 1993 and received his doctorate degree in medicine the same year. From 1993-1995 he worked as a Research Fellow at Thomas Jefferson University in Philadelphia and published several scientific papers

in the area of acute renal failure and hemodialysis. He worked from 1996-1998 as Product Manager Acute Therapies at Fresenius Medical Care in Bad Homburg and Milano and from 1999-2000 as Senior Consultant for Gemini Consulting in Bad Homburg. Christian B. Teig, CompuGroup Medical AG

Mr. Christian B. Teig was born in Oslo, Norway, in 1965. In October 2008, he was appointed Financial Director (CFO) of CompuGroup Medical AG. Prior to his appointment, Christian B. Teig held the position as CEO of Profdoc ASA, a Norwegian listed e-Health company. Before Christian B. Teig started to work for Profdoc in 2000, he worked in the technology sector for Norsk Data and as a management consultant for McKinsey & Company. Christian B. Teig received his Bachelor of Science degree from the University of California (Santa Barbara) in 1990 and his Master of Business Administration degree from INSEAD (France) in 1995.

15

Life Science Conference Prof. Dr. Jörg Vienken, Fresenius Medical Care Deutschland

Prof. Dr. Ing. Joerg Vienken has a degree in Chemical Engineering from the Technical University of Darmstadt and a Doctoral Degree in Biophysics & Engineering from the Technical University of Aachen (RWTH), both in Germany. After working as an Assistant Professor at the Institute for Biotechnology at Würzburg University, he is active in the medical device industry since more than 25 years. His focus is on medical device technology, biomaterials and artificial organs. Until moving to his recent position as Vice President "BioSciences" at Fresenius Medical Care in Bad Homburg, he was Head of the Department of Scientific Services at Akzo Nobel Membrana, Wuppertal, both in Germany.

Jörg Vienken has authored more than 300 publications & book chapters and 6 books with subject to the Medical Device Industry, biological and artificial membranes, biomaterials, biocompatibility and nephrology issues, as well as on Artificial Organs. He is member of the Editorial Board of several scientific journals dedicated to Biomaterials, Artificial Organs and Medical Device Technology. JV currently served as President of the International Federation for Artificial Organs (IFAO) from 2009-2011, with IFAO being the umbrella society for the continental Artificial Organs Societies, ASAIO (USA), JSAO (Japan) and ESAO (Europe). He is currently the Chairman of the Board of the German Association of Biotech Companies (VBU). Dr. Volker Wendel, AMEOS Group

AMEOS Group, founded 2002 in Zurich, is a leading provider of integrated healthcare services throughout the German-speaking region. The company operates an extensive network with more than 50 facilities encompassing both acute general and psychiatric hospitals as well as long-term mental and elderly care facilities.

Dr. Volker Wendel is Chief Financial Officer of AMEOS Group since 2007. His areas of responsibility include financial reporting, controlling, budgeting, strategic planning, financing and cash management. Prior to AMEOS Dr. Wendel spent four years at the University Hospital of Essen

where he worked as Vice Administrative Director, Head of Corporate Planning and Managing Director of West German Proton Therapy Center Essen (WPE) GmbH. In the latter function, he was responsible for the so far biggest Public Private Partnership (PPP) project in the German healthcare industry. Between 2001 and 2003, Dr. Wendel spent time as a consultant with Roland Berger in their Public Services/Healthcare sector team, where he consulted particularly healthcare service providers, public institutions and non-profit organizations.

Born in 1971, Dr. Wendel studied economics and business administration at the Universities of Freiburg and Mannheim and earned his PhD in business administration from the University of Mannheim. During his doctoral studies at the Chair of Public & Nonprofit Management, he did some research projects in the United States, Canada and Australia.

16

Life Science Conference

Sponsors DZ BANK GROUP PARTNER IN THE VOLKSBANKEN RAIFFEISENBANKEN COOPERATIVE FINANCIAL NETWORK The DZ BANK Group forms part of the German cooperative financial network, which comprises more than 1,100 local cooperative banks and is one of Germany‘s largest private-sector financial services organizations measured in terms of total assets. Within the cooperative financial network, DZ BANK AG functions both as a central institution for over 900 cooperative banks and their 12,000 branch offices and as a corporate bank. The DZ BANK Group includes Bausparkasse Schwäbisch Hall, DG HYP, DZ PRIVATBANK Group, R+V Versicherung, TeamBank, Union Investment Group, VR LEASING, and various other specialized institutions. With their strong brands, the companies of the DZ BANK Group constitute key pillars in the range of financial products and services offered by the cooperative financial network. The DZ BANK Group sets out its strategy and range of services for the cooperative banks and their customers through its four strategic business lines – retail banking, corporate banking, capital markets, and transaction banking. This combination of banking, insurance, home savings, and personal investment products and services has a long and successful tradition in the cooperative financial network. The specialized institutions in the DZ BANK Group provide top-class, highly competitive products at reasonable prices within their specific areas of expertise. This ensures that the cooperative banks in Germany are able to offer their clients a comprehensive range of outstanding financial services. PwC PwC. 8,900 dedicated people at 28 locations. € 1.45 billion in turnover. The leading auditing and consulting firm in Germany.

Our clients face diverse challenges, strive to put new ideas into practice and seek expert advice. They turn to us for comprehensive support and practical solutions that deliver maximum value. Whether for a global player, a family business or a public institution, we leverage all of our assets: experience, industry knowledge, high standards of quality, commitment to innovation and the resources of our expert network in over 158 countries. Building a trusting and cooperative relationship with our clients is particularly important to us – the better we know and understand our clients’ needs, the more effectively we can support them.

17

Company Profile

As one of the world’s leading exchange organisations Deutsche Börse Group provides

investors, financial institutions and companies access to global capital markets. Our

business covers the entire process chain from securities and derivatives trading, clearing,

settlement and custody, through to market data and the development and operation of

electronic trading systems.

Our reliable systems and our integrity as a neutral provider form the basis of our business

philosophy. We operate to the most exacting standards to create products and services to

meet the needs of international financial markets. As a listed company we work to create

value for our customers and our shareholders.

The Deutsche Börse business model is based on liquidity of stock trading and by thus is

align with the interests of the listed company. Due to this Deutsche Börse is offering its

professional and efficient listing platform and services to facilitate the development of the

listed company entering the European market and to meet the need of investors.

18

Mayer Brown llpBockenheimer Landstraße 98 -10060323 Frankfurt am MainGermany

Mayer Brown llpGraf-Adolf-Platz 1540213 DüsseldorfGermany

Mayer Brown LLP is a limited liability partnership established under the laws of the State of Illinois, U.S.A.

Americas | Asia | Europe | www.mayerbrown.com

Mayer Brown is a leading global law firm with offices in major cities across the Americas, Asia and Europe.

The unique opportunities and challenges of the life sciences industry require specific legal know-how, technological expertise and international advice from an entrepreneurial perspective.Our clients include life sciences companies as well as banks, funds, investment banks and other investors in the life sciences sector. Our geographic reach and on-the-ground presence in most of the world’s key business and finance centers allow us to assist our clients in structuring and coordinating their transactions and legal matters.

Our in-depth experience in the life sciences sector, gained by working across business areas and issues with life sciences companies and networking with leading industry organizations, provides us with the necessary insights for handling the legal and regulatory challenges facing the globalpharmaceuticals, biotech and medical device industries.

For solutions with a future.

Dr. Dr. Adem Koyuncu Partner – Lawyer and PhysicianCo-Head Global Life Sciences PracticeT: +49 211 86224 283akoyuncu@mayerbrown.com

Please visit our websites:Life Sciences: www.mayerbrown.com/lifesciencesCapital Markets: www.mayerbrown.com/capitalmarkets

Your contact in Germany:

Global Solutions. Local Strength.

19

Life Science Conference

Organizational Details

DVFA Center Mainzer Landstrasse 37-39 60329 Frankfurt am Main

It will be possible to reach you and the DVFA team during the conference at the following number:

Phone: +49 / 69 / 24 24 94 08 Fax: +49 / 69 / 24 24 94 09

DVFA Center Mainzer Landstrasse 37-39 60329 Frankfurt am Main

Event Management

Heike Hambuch eMail: hh@dvfa.de

Technical Support

Viktor Bart eMail: vb@dvfa.de

DVFA GmbH Phone: +49 / 69 / 26 48 48 0 Fax: +49 / 69 / 26 48 48 489 www.dvfa.de

Managing Director

Ralf Frank eMail: rf@dvfa.de, Phone: +49 / 69 / 26 48 48 0

Financial Communication

Karin Wenzel eMail: kw@dvfa.de, Phone: +49 / 69 / 26 48 48 101

Contact Details Life Science Conference

Contact Details DVFA GmbH

Venue

20

Michael E. Porter, Harvard Business School, Institute for Strategy and Competitiveness, Boston, MA, USA; Clemens Guth, Munich, Germany

Redefining German Health Care Moving to a Value-Based System

The German health care system is on a collision course with budget realities. Costs are high and rising, and quality problems are becoming ever more apparent. Decades of reforms have produced little change to these troubling trends.

Why has Germany failed to solve these cost and quality problems? The reason is that Germany has not set value for patients as the overarching goal, defined as the patient health outcomes achieved per euro expended.

This book lays out an action agenda to move Germany to a high value system: care must be reorganized around patients and their medical conditions, providers must compete around the outcomes they achieve, health plans must take an active role in improving subscriber health, and payment must shift to models that reward excellent providers. Also, private insurance must be integrated in the risk-pooling system.

These steps are practical and achievable, as numerous examples in the book demonstrate. Moving to a value-based health care system is the only way for Germany to continue to ensure access to excellent health care for everyone.

2012 Approx. 330 p. Hard cover

► € 49.95 | £ 44.99 |

ISBN: 978-3-642-10825-9

forthcoming

Yes, please send me

____ copies Porter/Guth, Redefining German Health Care ISBN: 978-3-642-10825-9 ► € 49.95 | £ 44.99

Testimonials

We must thank the authors of Redefining German Health Care for changing the language of the current health care debate. Their book makes a passionate argument for moving the health care discussion beyond cost control, health insurance premiums and risk pooling. It is health outcomes that matter to patients, not insurance premiums per se.

Prof. Dr. Dr. Dr. Eckhard Nagel, Institute for Medical Management and Health Sciences University of Bayreuth and Chief Medical Officer University Hospital Essen, Germany

The introduction of competition among health insurances in Germany was successful. However, it is long overdue to instil value-adding competition to the provider side. This is convincingly demonstrated by Michael Porter and Clemens Guth in their excellent adaption of the original Redefining Health Care book.

Prof. Dr. Norbert Klusen, Chief Executive Officer Techniker Krankenkasse, Hamburg, Germany

In the book Redefining German Health Care, Michael Porter and Clemens Guth establish clear, actionable steps which providers and health plans should take to maximize patient value. They argue that every provider should focus their service lines, measure outcomes and organise integrated care around medical conditions. This book is inspiring and a must read for health care managers.

Prof. Dr. Karl Max Einhäupl, Chief Executive Officer Charité – Universitätsmedizin, Berlin, Germany

Physicians and provider organizations must make outcome measurement core to their activities. Outcome measurement demonstrates that not the volume but the results of care matter. Superior providers will benefit from transparency of results, either through pay-for-performance or simply through more patients. Redefining German Health Care shows us convincingly how we can embark on this course.

Professor Dr. Dr. h.c. Peter C. Scriba, Chairman of the Research Board of the German Medical Association, former Vice-President of Health Care Advisory Council and Chief Medical Officer of Ludwig-Maximilians-University Hospital, Munich, Germany

The book “Redefining German Health Care” by Michael Porter and Clemens Guth provides a fact-based analysis of the development of the German health care system. On the one hand, the analysis and assessment demonstrates the system’s substantial achievements (also with respect to other countries), while, on the other hand, it speaks clearly about the system’s shortcomings, which are highlighted by concrete examples. The reader is presented with logical arguments for structurally changing the health care system, building on the already achieved benefits. Both authors rightly assume that better quality in conjunction with appropriate financing and incentive schemes will lead to higher cost efficiency, as shown in other industries. The system will not improve without an honest debate over the current system’s challenges. This book makes a significant contribution to that process.

Prof. Dr. Jürgen Wettke, Director Healthcare Practice McKinsey & Company, Duesseldorf, Germany

DVFAGmbHKarin WenzelFinancial CommunicationTel.: +49 (0) 69 26 48 48 101Fax: +49 (0) 69 26 48 48 489Mail: kw@dvfa.deWeb: www.dvfa.de

Content: DVFA GmbHDesign: ReichDesign, FrankfurtPicture: www.shutterstock.com Subject to modifications. Copyright 2012 DVFA GmbH.

VenueDVFA CenterMainzer Landstrasse 37-39D-60329 Frankfurt am MainTel.: +49 (0) 69 24 24 94 08

DVFA–SocietyofInvestmentProfessionalsinGermany

DVFA is the Society of Investment Professionals in Germany, founded in 1960. Currently, DVFA has approx. 1,600 individual members representing over 400 investment firms, banks, asset managers, consultants and counselling businesses. DVFA assures the credibility of the professionals and the integrity of the market by offering internationally recognised qualification programmes, by providing platforms for professional financial communication, and by effective self-regulation.

Via EFFAS, the umbrella organisation of European Analysts Societies, DVFA offers access to a pan-European network with more than 17,000 investment professionals in 26 nati-ons. Via ACIIA, the Association of Certified International Investment Analysts, DVFA is part of a worldwide network of more than 60,000 investment professionals.